Skip to content

Study · Non-randomized trial · n = 23 · 2004

1 result

Efficacy of lanreotide 30 mg on prevention of pain relapse after oral refeeding in patients with necrotizing acute pancreatitis. A phase II prospective multicentre study.

Lévy P, Hastier P, Arotçarena R, Bartolie E, Bougeard-Julien M, Blumberg J, O'Toole D, Ruszniewski P

Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.]12 May 2004Cited by 8 (Europe PMC)

PMID15148442 (opens in a new tab)DOI10.1159/000078434 (opens in a new tab)PepBankPUB-15148442
Publisher pagePubMedAsk about this study
Jump to 1 result

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study1

1 result from studies that gave the peptide. 1 result from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In necrotizing acute pancreatitis patients given lanreotide, 1 patient (4.3 %) developed pain 3 days after refeeding.

    In plain wordsIn necrotizing acute pancreatitis patients given lanreotide, one patient developed pain after refeeding.

    Peptide
    Lanreotide
    Outcome
    Not applicablePain relapse after refeeding
    Study

    n = 23

    Outcome group
    Pain · Gastrointestinal
    Studied dose
    30 mg · intramuscular · one injection on the day before refeedingAs given in this study (human).

    Measurements

    patients with pain relapse after refeeding
    1 patients
    lanreotide 30 mg before refeeding
    patients with pain relapse after refeeding
    4.3%
    lanreotide 30 mg before refeeding

    Source sentences

    Summary
    Only 1 patient (4.3 %) had pain occurring 3 days after refeeding.
    2 context sentences
    Summary · context
    AIMS, PATIENTS AND METHODS: To assess the frequency of pain relapse in patients with acute necrotizing pancreatitis after treatment with one intramuscular injection of lanreotide 30 mg on the day before refeeding.
    Summary · context
    23 patients were included in 4 centres.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:36 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.